000077204 001__ 77204
000077204 005__ 20200117221627.0
000077204 0248_ $$2sideral$$a110479
000077204 037__ $$aART-2018-110479
000077204 041__ $$aeng
000077204 100__ $$aTorres-Ferrus, M.
000077204 245__ $$aPrevenBox: Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in migraine
000077204 260__ $$c2018
000077204 5060_ $$aAccess copy available to the general public$$fUnrestricted
000077204 5203_ $$aP114
Background: OnabotulinumtoxinA is an effective, tolerable and safepreventive treatment for chronic migraine (CM). Other than a reduc-tion in headache frequency or disability, in CM the withdrawal ofconcomitant preventive medication indicates treatment effectivenessand quality of life improvement.
Objective: To characterize the change in the use of oral preventivemedication after treatment with OnabotulinumtoxinA in patientswith migraine.
Methods: This is a multicentre study. We consecutively included pa-tients with migraine (ICHD-3) that were on preventive treatment withOnabotulinumtoxinA. We retrospectively collected demographic data, diagnosis of migraine, frequency and intensity changes, number ofcycle and OnabotulinumtoxinA dose. In addition, we listed the initialand current preventive treatment (number of drugs and group) andthe number and cycle of medications withdrawn. We performed aunivariate and logistic regression analysis.
Results: We included 542 patients: 87.6% women, mean age 47.6 ±11.7 years. A 89.3% had chronic migraine and 10.8% had high fre-quency episodic migraine. The mean reduction in frequency aftertreatment was 13.4±8.2 headache days/month. At baseline, a 91.3%took other preventives and during treatment with Onabotulinumtox-inA a 58.6% withdrew at least one drug, 25.8% stopped completelyall oral preventive drugs. Factors associated with withdrawal were:being male, having >50% response in frequency and intensity, thenumber of infiltrations and a shorter chronification period until thefirst OnabotulinumtoxinA administration (p <0.05). The multivariateanalysis showed that a better response in intensity (OR:1.8 [1.4-2.2], p<0.001), a greater number of infiltrations (OR:1.1 [1.0-1.2], p<0.001)and a shorter chronification period (OR:0.994 [0.992-0.997], p<0.001)were predictors of withdrawal. The ROC curve, showed that 6 Onabo-tulinumtoxinA cycles was the cut-off point that better predicted oralpreventive medication withdrawal (p <0.001).
Conclusions: Treatment with OnabotulinumtoxinA reduces the use ofother preventive medications for migraine. The highest probability ofwithdrawal occurs after 6 cycles of treatment.
000077204 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000077204 590__ $$a3.918$$b2018
000077204 591__ $$aCLINICAL NEUROLOGY$$b46 / 199 = 0.231$$c2018$$dQ1$$eT1
000077204 591__ $$aNEUROSCIENCES$$b79 / 266 = 0.297$$c2018$$dQ2$$eT1
000077204 592__ $$a1.106$$b2018
000077204 593__ $$aAnesthesiology and Pain Medicine$$c2018$$dQ1
000077204 593__ $$aNeurology (clinical)$$c2018$$dQ1
000077204 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000077204 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000077204 700__ $$0(orcid)0000-0001-5139-6031$$aSantos Lasaosa, S.$$uUniversidad de Zaragoza
000077204 700__ $$aPeral, A.G.
000077204 700__ $$aLainez, J.M.
000077204 700__ $$aViguera Romero, J.
000077204 700__ $$agago Veiga, A.B.
000077204 700__ $$aIrimia, P.
000077204 700__ $$aSanchez del Rio, M.
000077204 700__ $$aAsskour, L.
000077204 700__ $$aGallardo, V.J.
000077204 700__ $$aPozo-Rosich, P.
000077204 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000077204 773__ $$g19, Suppl. 1 (2018), P114 [1 pp]$$pJ. headache pain$$tThe Journal of headache and pain$$x1129-2369
000077204 85641 $$uhttps://thejournalofheadacheandpain.biomedcentral.com/track/pdf/10.1186/s10194-018-0900-0$$zTexto completo de la revista
000077204 8564_ $$s73808$$uhttps://zaguan.unizar.es/record/77204/files/texto_completo.pdf$$yVersión publicada
000077204 8564_ $$s111901$$uhttps://zaguan.unizar.es/record/77204/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000077204 909CO $$ooai:zaguan.unizar.es:77204$$particulos$$pdriver
000077204 951__ $$a2020-01-17-21:58:09
000077204 980__ $$aARTICLE